Breast Cancer Treatment Guidelines

Introduction to Breast Cancer Guidelines

The National Comprehensive Cancer Network recommends a multidisciplinary approach to breast cancer treatment based on molecular subtypes, with treatment decisions guided by tumor characteristics including hormone receptor status, HER2 status, and stage of disease 1

The European Society for Medical Oncology recommends annual or biennial mammography for women aged 50-69 years (Level of Evidence I, Grade A) 2
For women aged 40-49 and 70-74 years, regular mammography may be performed, though evidence for benefit is less established (Level of Evidence II, Grade B) 2
Women with a strong family history of breast cancer or BRCA mutations should undergo annual MRI alternating with mammography/ultrasound every 6 months (Level of Evidence III, Grade A) 2

The European Society for Medical Oncology recommends that breast imaging include bilateral mammogram and ultrasound of breasts and axillae (Level of Evidence I, Grade A) 2
MRI is recommended when standard imaging is inconclusive or in special clinical situations (Level of Evidence I, Grade A) 2
Pathological evaluation must include histology from the primary tumor and cytology/histology of axillary nodes if involvement is suspected 2
Pathology reports should include histological type, grade, and immunohistochemical evaluation of ER, PR, HER2, and proliferation markers like Ki67 2
Tumors should be categorized into surrogate intrinsic subtypes based on routine histology and immunohistochemistry 2
Genetic counseling and testing for BRCA1/2 mutations should be offered to high-risk patients 2

Disease staging should follow the TNM system with documentation of hormone receptor status 2, 3
Routine staging includes complete blood counts, chemistry panel, chest X-ray, and contralateral mammography 3
Additional imaging (bone scan, abdominal ultrasound/CT) should be performed only if clinically indicated by symptoms or laboratory findings 3

CDK4/6 inhibitors combined with endocrine therapy have shown significant progression-free survival benefits and are recommended for appropriate patients with hormone receptor-positive/HER2-negative breast cancer 4
Sequential monotherapy is preferred over combination chemotherapy for advanced disease unless there is rapid clinical progression or life-threatening visceral metastases 5
For advanced HER2+ disease, trastuzumab with vinorelbine or a taxane is preferred for first-line therapy 6
Dual HER2 blockade with trastuzumab and pertuzumab can be combined with docetaxel, weekly paclitaxel, vinorelbine, or nab-paclitaxel 6
Chemotherapy remains the primary systemic treatment option for triple-negative breast cancer 6
For previously treated patients with anthracyclines with/without taxanes, carboplatin has shown comparable efficacy with a more favorable toxicity profile compared to docetaxel 6

Sentinel lymph node biopsy is the preferred method for axillary staging in clinically node-negative patients 7
For patients with 1-2 positive sentinel nodes undergoing breast conservation with whole-breast radiation, completion axillary lymph node dissection may be avoided (based on ACOSOG Z0011 criteria) 4

Whole breast radiation is recommended after breast-conserving surgery (Category 1) 8
For patients with ≥4 positive nodes, radiation to the chest wall, infraclavicular region, supraclavicular area, and internal mammary nodes is recommended (Category 1) 8
For patients with 1-3 positive nodes, radiation to these regions should be strongly considered 8
Women aged 70+ with ER-positive, clinically node-negative early breast cancer may omit radiation after lumpectomy if receiving endocrine therapy 7

For HR-positive/HER2-negative advanced disease, endocrine therapy partnered with targeted agents (CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors) is preferred over chemotherapy 4
For triple-negative advanced breast cancer, there are no specific chemotherapy recommendations different from other HER2-negative disease 6

History and physical examination every 3-6 months for 3 years, then every 6-12 months thereafter 3
Tumor markers may be used to evaluate response to treatment in patients with non-measurable metastatic disease, but should not be used alone to initiate treatment changes 5
Evaluation of response to therapy should generally occur every 2-4 months for endocrine therapy or after 2-4 cycles of chemotherapy 5